Viewing Company Abbott Labs | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Abbott Labs Stock Symbol: ABT-N

Last Price Recorded: $38.5500 on 2016-05-03

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2014-02-04 PAST TOP PICK Christine Poole

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.


Price:
$36.250
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2014-01-29 DON'T BUY Gordon Reid

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.


Price:
$35.850
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2014-01-02 BUY Gordon Reid

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.


Price:
$38.230
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2013-12-23 COMMENT Barry Schwartz

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.


Price:
$38.440
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2013-12-09 TOP PICK Gavin Graham

Spun off drug side.  It is medical devices and has been one of the most consistent growers over the last decade.  Reasonably priced, 2.5% yield.


Price:
$37.200
Subject:
GLOBAL & NORTH AMERICAN LARGE
Bias:
BULLISH
Owned:
Yes
2013-11-29 PAST TOP PICK Brian Acker, CA

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company


Price:
$38.190
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2013-11-01 TOP PICK Stuart Hinshelwood

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.


Price:
$36.960
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Yes
2013-10-30 PAST TOP PICK Mohsin Bashir

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.


Price:
$36.940
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2013-10-29 TOP PICK Christine Poole

Adult and infant nutritionals.  Generics, very emerging market focused, diversified.  Good earnings growth going forward.  Very shareholder friendly.  Increasing dividend should attract more shareholders. 


Price:
$37.280
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2013-10-10 PAST TOP PICK David Burrows

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well.  He sold ABT.


Price:
$33.640
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
No
2013-10-04 HOLD Gordon Reid

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.


Price:
$33.560
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2013-09-19 TOP PICK Stuart Hinshelwood

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.


Price:
$35.340
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2013-09-18 PAST TOP PICK Hap (Robert) Sneddon FCSI

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.


Price:
$35.650
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
NEUTRAL
Owned:
Yes
2013-07-29 TOP PICK Hap (Robert) Sneddon FCSI

Just moved up stop loss to $34.90 (200 day moving average).  They are in the right space.  Nutritional component looks to be just in the beginning of a long term uptrend.


Price:
$36.740
Subject:
TECHNICAL ANALYSIS
Bias:
SELECTIVE
Owned:
Yes
2013-07-09 TOP PICK Christine Poole

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.


Price:
$34.740
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
Showing 16 to 30 of 92 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.